SG11202006313WA - Injectable compositions of triterpenoid antifungals encapsulated in liposomes - Google Patents

Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Info

Publication number
SG11202006313WA
SG11202006313WA SG11202006313WA SG11202006313WA SG11202006313WA SG 11202006313W A SG11202006313W A SG 11202006313WA SG 11202006313W A SG11202006313W A SG 11202006313WA SG 11202006313W A SG11202006313W A SG 11202006313WA SG 11202006313W A SG11202006313W A SG 11202006313WA
Authority
SG
Singapore
Prior art keywords
triterpenoid
antifungals
liposomes
encapsulated
injectable compositions
Prior art date
Application number
SG11202006313WA
Inventor
Rajeshwar Motheram
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of SG11202006313WA publication Critical patent/SG11202006313WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202006313WA 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes SG11202006313WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Publications (1)

Publication Number Publication Date
SG11202006313WA true SG11202006313WA (en) 2020-07-29

Family

ID=65024141

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006313WA SG11202006313WA (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Country Status (27)

Country Link
US (2) US20200338002A1 (en)
EP (2) EP4137123A1 (en)
JP (2) JP7378401B2 (en)
KR (1) KR20200105875A (en)
CN (2) CN111655237B (en)
AU (1) AU2018399599B2 (en)
BR (1) BR112020013448A2 (en)
CA (1) CA3087176A1 (en)
DK (1) DK3735226T3 (en)
EA (1) EA202091626A1 (en)
ES (1) ES2927051T3 (en)
HR (1) HRP20221295T1 (en)
HU (1) HUE060400T2 (en)
IL (1) IL275758A (en)
LT (1) LT3735226T (en)
MA (1) MA51514A (en)
MD (1) MD3735226T2 (en)
MX (1) MX2020006992A (en)
PL (1) PL3735226T3 (en)
PT (1) PT3735226T (en)
RS (1) RS63687B1 (en)
SA (1) SA520412362B1 (en)
SG (1) SG11202006313WA (en)
SI (1) SI3735226T1 (en)
TW (1) TW201929853A (en)
UA (1) UA126096C2 (en)
WO (1) WO2019135954A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US20050238705A1 (en) * 2004-01-14 2005-10-27 Ning Hu Lipid-based dispersions useful for drug delivery
WO2007126900A2 (en) 2006-04-03 2007-11-08 Merck & Co., Inc. Antifungal agents
AU2008307664B2 (en) * 2007-09-28 2013-01-31 Scynexis, Inc. Antifungal agents
AU2009240389A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
JP5548875B2 (en) * 2008-08-12 2014-07-16 サイネクシス,インコーポレーテッド Antifungal
ES2913111T3 (en) * 2015-01-19 2022-05-31 Scynexis Inc Novel salts and polymorphs of SCY-078

Also Published As

Publication number Publication date
MA51514A (en) 2021-04-07
MD3735226T2 (en) 2023-03-31
IL275758A (en) 2020-08-31
EP3735226B1 (en) 2022-08-10
US20230277455A1 (en) 2023-09-07
AU2018399599A1 (en) 2020-07-16
CN111655237A (en) 2020-09-11
BR112020013448A2 (en) 2020-12-01
RS63687B1 (en) 2022-11-30
HRP20221295T1 (en) 2022-12-23
TW201929853A (en) 2019-08-01
PL3735226T3 (en) 2022-12-19
US20200338002A1 (en) 2020-10-29
EA202091626A1 (en) 2020-09-22
UA126096C2 (en) 2022-08-10
AU2018399599B2 (en) 2022-09-01
EP4137123A1 (en) 2023-02-22
CA3087176A1 (en) 2019-07-11
JP7378401B2 (en) 2023-11-13
JP2024012452A (en) 2024-01-30
SA520412362B1 (en) 2022-12-15
LT3735226T (en) 2022-11-10
WO2019135954A1 (en) 2019-07-11
HUE060400T2 (en) 2023-02-28
KR20200105875A (en) 2020-09-09
ES2927051T3 (en) 2022-11-02
CN115998684A (en) 2023-04-25
PT3735226T (en) 2022-09-20
CN111655237B (en) 2023-02-03
MX2020006992A (en) 2020-09-09
JP2021508728A (en) 2021-03-11
DK3735226T3 (en) 2022-10-24
EP3735226A1 (en) 2020-11-11
SI3735226T1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
HK1252870A1 (en) Sirp polypeptide compositions and methods of use
ZA201707975B (en) Improvements in or relating to encapsulated perfume compositions
IL286391A (en) Fenfluramine compositions and methods of preparing the same
GB2573668B (en) Accelerators for composite cement compositions
HK1254327A1 (en) Cosmetic composition in the form of anhydrous powder preparation
ZA201800568B (en) Encapsulated stabilizer compositions
ZA201707938B (en) Improvements in or relating to encapsulated perfume compositions
IL247550B (en) Sialylated glycoprotein compositions and uses thereof
IL275758A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
SI3370756T1 (en) Combination of canrenoate and exenatide
IL277802A (en) Injectable composition
IL257199A (en) Encapsulated stabilizer compositions